Characterization of a Novel Neutralizing Monoclonal Antibody Against Ebola Virus GP.
J Infect Dis
; 212 Suppl 2: S372-8, 2015 Oct 01.
Article
en En
| MEDLINE
| ID: mdl-26232760
ABSTRACT
Ebola virus is the etiological agent of a severe hemorrhagic fever with a high mortality rate. As the only protein exposed on the surface of viral particles, the spike glycoprotein GP is the unique target for neutralizing monoclonal antibodies. In this study, we demonstrate the strong neutralization capacity of the monoclonal antibody #3327 and characterize its activity. GP residues that are required for recognition and neutralization were found to be located both in the internal fusion loop and in the receptor-binding domain. Analysis of Ebola virus entry in the presence of #3327 allows us to hypothesize that this antibody binds to the virus particle before internalization and endosomal processing of GP and likely prevents the final viral fusion step. Importantly, #3327 is able to block entry of virions bearing GP that contain the Q508 escape mutation common to a number of virus-neutralizing antibodies, and therefore provides future perspectives for treatment strategies against Ebola virus infection.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Ebolavirus
/
Anticuerpos Neutralizantes
/
Anticuerpos Monoclonales
/
Anticuerpos Antivirales
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Infect Dis
Año:
2015
Tipo del documento:
Article
País de afiliación:
Francia